Study S003241

A Multicenter, Randomized, Double-blind, Placebo-Controlled , Phase 3 Study Comparing the Efficacy and Safety of HDM1005 Versus Placebo in Subjects With T2DM Inadequate Glycemic Control With Diet and Exercise Alone

ClinicalTrials.gov record

Registration

Registration: NCT07394114
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 240
Start: 2026-02-24
Primary completion: 2027-08-28
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:HDM1005 injection or placebo
Results posted: FALSE

Registered primary outcomes

Change from baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.